Evidence map›Paper›PMID 34375508›Full record

ArticleFEBS open bio2021

Hemin activation abrogates Mycoplasma hyorhinis replication in chronically infected prostate cancer cells via heme oxygenase-1 induction.

Hanxia Huang, Alena Dabrazhynetskaya, Jacob Pluznik, Jiwen Zheng, Yong Wu, Vladimir Chizhikov, Paul W Buehler, Kenneth M Yamada, Subhash Dhawan

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in FEBS open bio, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Hanxia HuangCenter for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.ORCID 0000-0002-1753-7053
Alena DabrazhynetskayaCenter for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
Jacob PluznikCenter for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.ORCID 0000-0003-0925-9417
Jiwen ZhengOffice of Science and Engineering Laboratories, Center for Devices and Radiological Health, Food and Drug Administration, Silver Spring, MD, USA.
Yong WuOffice of Science and Engineering Laboratories, Center for Devices and Radiological Health, Food and Drug Administration, Silver Spring, MD, USA.
Vladimir ChizhikovCenter for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
Paul W BuehlerCenter for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
Kenneth M YamadaNational Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA.
Subhash DhawanCenter for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.ORCID 0000-0001-5241-5302
Center for Biologics Evaluation and Research · USCenter for Devices and Radiological Health · USNational Institutes of Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mycoplasma hyorhinis (M. hyorhinis) lacks a cell wall and resists multiple antibiotics. We describe here the striking > 90% inhibitory effect of hemin, a natural inducer of the cytoprotective enzyme heme oxygenase-1 (HO-1), on M. hyorhinis replication in chronically infected LNCaP prostate cancer cells. The role of HO-1 in interrupting M. hyorhinis replication was confirmed by HO-1-specific siRNA suppression of hemin-induced HO-1 protein expression, which increased intracellular M. hyorhinis DNA levels in LNCaP cells. Proteomic analysis and transmission electron microscopy of hemin-treated cells confirmed the complete absence of M. hyorhinis proteins and intact microorganisms, respectively, strongly supporting these findings. Our study is the first to our knowledge suggesting therapeutic potential for activated HO-1 in cellular innate responses against mycoplasma infection.

Indexed as

Mycoplasma hyorhinisProstatic NeoplasmsHeme Oxygenase-1HeminHumansMaleProteomicsHeme Oxygenase-1Heminheme oxygenase-1host defenseinfectious diseaseinnate immunityMycoplasma hyorhinisprostate cancer

Identifiers

PMID34375508
PMCPMC8487054
OpenAlexW3188590143

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.